

ABRIDGED UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS FOR THE QUARTER AND NINE MONTHS ENDED 30 NOVEMBER 2018

**DIRECTORS' COMMENTARY
 BACKGROUND**

The Company was incorporated on 1 October 2010 as a public company limited by shares under the Mauritian Companies Act.

Go Life is registered in the Republic of Mauritius and was listed on the Stock Exchange of Mauritius ("SEM") on 7 July 2011. The Company successfully completed a secondary listing on the Alternative Exchange ("AltX") of the Johannesburg Stock Exchange ("JSE") on 23 November 2016.

PRIMARY OBJECTIVE

The initial focus of the Company was to compete in the supplementary nutraceutical and cosmeceutical markets by offering natural compounds that have been subjected to study and clinical trials. The focus has shifted somewhat, and Go Life is now a multi-faceted healthcare company, offering a comprehensive, all-inclusive product range to address market needs in the pharmaceutical, generic, nutraceutical and cosmeceutical markets. In addition, Go Life now offers a range of medicinal consumables and high-end sophisticated hospital equipment.

Being a nutraceutical company at heart, the advantages contained in medicinal cannabis could no longer be ignored. Go Life has positioned itself strategically to enter the cannabis cultivation market and in so doing, favourably positions itself to manufacture innovative and appropriate cannabis derived medicinal products.

RESULTS COMMENTARY

Revenue grew by 87.29% for the three months ended 30 November 2018 ("Q3") to USD 2 380 389 compared to, USD 1 270 983 reported at the prior three-months ended 31 August 2018 ("Q2"). The growth in revenue is attributed to the performance and the continuous popularity of the nutraceutical range offered in Gotha. Pending negotiations on acquiring an elevated portion (currently 50%) is in process. An announcement in this regard is anticipated shortly.

Profit from operations increased by 83.64% for Q3 to USD 894 716 from USD 487 199 in Q2.

Income from associates increased by 46.16% to USD 114 839 (Q3) from USD 78 569 (Q2) and is derived from the associate interest in Bon Health frail care operations.

COMPANY OUTLOOK

Go Life is currently in the process of incorporating medicinal cannabis into its nutraceutical products range. To this end, Go Life is at an advanced stage of negotiating a settlement to acquire a majority stake in Aziza Healthcare and the cultivating division known as Choice Organics. An announcement in this regard will follow soon.

The potential acquisition Aziza Healthcare favourably positions Go Life towards bringing innovative ways of accurately administering medicinal cannabis.

Extensive research was conducted on developing channels for Gotha Health Products. To this end, Cosmetic Connection has been identified as an excellent channel for the Gotha range of products. Cosmetic Connection has 40 branches across South Africa, and is an ideal vehicle to introduce Gotha Health Products to a wider South African market.

Go Life has also recently partnered with The Ingonyama Trust, which represents and manages King Goodwill Zwelithini kaBhekuzulu's land in KwaZulu Natal, with the aim of increasing the Gotha Health Products preventative medical offering.

The transaction with Ascendis Health Direct, as announced on 4 September 2018, has been delayed due to certain conditions precedent that have not yet been fulfilled. The parties are in the process of resolving the outstanding matters, which are expected to be finalised imminently.

RELATED PARTY TRANSACTIONS

There were no transactions with related parties that are material to an understanding of these results.

DIVIDENDS

No dividends were authorized or paid during the period under review.
 By order of the Board

31 January 2019

STATEMENT OF FINANCIAL POSITION

	THE GROUP Unaudited 9 MONTHS	THE GROUP Unaudited 9 MONTHS	THE GROUP Unaudited 6 MONTHS	THE GROUP Audited 12 MONTHS
	30 NOVEMBER 2018 USD	30 NOVEMBER 2017 USD	31 AUGUST 2018 USD	28 FEBRUARY 2018 USD
ASSETS				
Non - Current Assets	38 861 444	36 658 985	37 661 769	37 394 804
Investments in Associates	899 925	998 538	849 095	849 095
Intangible Assets	29 948 171	28 857 769	29 026 143	29 026 143
Property Plant and Machinery	8 013 348	6 802 678	7 786 531	7 519 566
Current Assets	1 286 729	1 088 572	1 313 558	856 012
Inventories	248 863	-	184 721	96 830
Trade and other Receivables	394 582	489 287	245 381	172 698
Cash and Cash Equivalents	643 284	599 285	883 456	572 724
Income taxes	-	-	-	13 760
TOTAL ASSETS	40 148 173	37 747 557	38 975 327	38 250 816
EQUITY				
Capital and Reserves	35 650 562	34 482 637	34 953 410	34 478 762
Share Capital	34 965 300	34 965 300	34 965 300	34 965 300
Accumulated Profit	685 262	(482 663)	(11 890)	(486 538)
Non-Distributable Reserves	-	-	-	-
Foreign Currency Translation Reserve	-	-	-	-
LIABILITIES				
Non - Current Liabilities	4 207 759	2 988 122	3 612 296	3 424 785
Loan - Shareholders	3 487 325	2 988 122	3 487 325	3 424 784
Loan - third party	720 434	-	124 971	-
Current Liabilities	289 852	276 798	409 623	347 269
Trade and other Payables	289 852	276 798	409 623	241 299
Income Tax	-	-	-	105 970
TOTAL EQUITY AND LIABILITIES	40 148 173	37 747 557	38 975 327	38 250 816

STATEMENT OF CHANGES IN EQUITY

	Share USD	Revenue USD	Total USD
Balance as at 31 August 2018	34 965 300	(11 890)	34 953 410
Balance as at 28 February 2018	34 965 300	(486 536)	34 478 764
Total Comprehensive Income for the period	-	697 152	697 152
Balance as at 30 NOVEMBER 2018	34 965 300	210 616	35 175 916

STATEMENT OF PROFIT AND OTHER COMPREHENSIVE INCOME

	THE GROUP Unaudited 3 MONTHS	THE GROUP Unaudited 9 MONTHS	THE GROUP Unaudited 9 MONTHS	THE GROUP Audited 6 MONTHS	THE GROUP Audited 12 MONTHS
	30 NOVEMBER 2018 USD	30 NOVEMBER 2018 USD	30 NOVEMBER 2017 USD	31 AUGUST 2018 USD	28 FEBRUARY 2018 USD
Revenue	1 109 406	2 380 389	1 568 463	1 270 983	1 819 213
Expenses	(701 889)	(1 445 673)	(899 794)	(783 794)	(1 015 261)
PROFIT FROM OPERATIONS	407 517	894 716	669 669	487 199	803 952
Share of profits - Associates	36 270	114 839	95 612	78 569	190 565
Finance Income	-	-	-	-	-
Finance costs	(105 422)	(312 403)	(213 192)	(206 981)	(313 103)
PROFIT BEFORE TAXATION	338 365	697 152	552 119	358 787	681 414
Taxation	-	-	-	-	(105 970)
NET PROFIT AFTER TAXATION	338 365	697 152	552 119	358 787	575 445
Other Comprehensive income	-	-	-	-	-
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	338 365	697 152	552 119	358 787	575 445

RECONCILIATION OF BASIC EARNINGS TO HEADLINE EARNINGS

	THE GROUP Unaudited 9 MONTHS	THE GROUP Unaudited 9 MONTHS	THE GROUP Unaudited 6 MONTHS	THE GROUP Audited 12 MONTHS
	30 NOVEMBER 2018 USD	30 NOVEMBER 2017 USD	31 AUGUST 2018 USD	28 FEBRUARY 2018 USD
Basic earnings	697 152	515 668	358 787	575 445
Headline earnings	697 152	515 668	358 787	575 445
Weighted average number of shares	900 000 000	900 000 000	900 000 000	900 000 000
Basic and diluted earnings per share (USD cents)	0.0775	0.0572	0.0399	0.0639
Headline earnings per share (USD cents)	0.0775	0.0572	0.0399	0.0639

STATEMENT OF CASH FLOWS

	THE GROUP Unaudited 9 MONTHS	THE GROUP Unaudited 9 MONTHS	THE GROUP Unaudited 6 MONTHS	THE GROUP Audited 12 MONTHS
	30 NOVEMBER 2018 USD	30 NOVEMBER 2017 USD	31 AUGUST 2018 USD	28 FEBRUARY 2018 USD
Net Cash (used in)/ from other operating activities	(68 054)	290 453	95 717	187 623
Cash from/(used in) investing activities				
Property, plant and equipment	226 817	(77 964)	5 749	2 303
Movement in net cash resources	158 763	212 489	101 476	189 926
Balance at the start of the year	572 724	386 796	627 292	382 798
Balance at the end of the period	731 487	599 285	728 768	572 724

SEGMENTAL REPORTING – 9 MONTHS ENDED 30 NOVEMBER 2017

	Health Products USD	Property USD	Frail care Associate USD	Total USD
Statement of net profit/loss				
Revenue	1 857 712	522 677	114 839	2 495 228
Interest expenses	-	(312 403)	-	(312 403)
Income Tax	-	-	-	-
Net profit/(loss) for the period	372 039	210 274	114 839	697 152
Statement of financial position				
Total Assets	29 945 837	7 519 566	849 095	38 314 498
Total Borrowings	(720 434)	(3 487 325)	-	(4 207 759)

SEGMENTAL REPORTING – 9 MONTHS ENDED 30 NOVEMBER 2017

	Nutraceutical USD	Property USD	Frail care Associate USD	Total USD
Statement of net profit/loss				
Revenue	926 717	546 134	95 612	1 568 463
Interest expenses	-	213 192	-	213 192
Income Tax	-	-	-	-
Net profit/(loss) for the period	136 189	320 822	95 612	552 623
Statement of financial position				
Total Assets	29 582 209	6 802 678	998 538	37 383 425
Total Borrowings	-	(2 988 122)	-	(2 988 122)

SEGMENTAL REPORTING – 6 MONTHS ENDED 31 AUGUST 2018

	Nutraceutical USD	Property USD	Frail care Associate USD	Total USD
Statement of net profit/loss				
Revenue	848 453	343 961	78 569	1 270 983
Interest expenses	(79 556)	(127 425)	-	(206 981)
Income Tax	-	-	-	-
Net profit/(loss) for the period	768 897	216 536	78 569	1 064 002
Statement of financial position				
Total Assets	29 882 155	7 519 566	849 095	38 250 816
Total Borrowings	1 212 348	2 212 436	-	3 424 784

SEGMENTAL REPORTING – 3 MONTHS ENDED 30 NOVEMBER 2018

	Nutraceutical USD	Property USD	Frail care Associate USD	Total USD
Statement of net profit/loss				
Revenue	1 009 259	178 716	36 270	1 224 245
Interest expenses	(79 556)	(184 978)	-	(264 534)
Income Tax	-	-	-	-
Net profit/(loss) for the period	929 703	(6 202)	36 270	1 118 823
Statement of financial position				
Total Assets	29 945 837	7 519 566	849 095	38 314 498
Total Borrowings	(720 434)	(3 487 325)	-	(4 207 759)

SEGMENTAL REPORTING – 12 MONTHS ENDED 28 FEB 2018

	Nutraceutical USD	Property USD	Frail care Associate USD	Total USD
Statement of net profit/loss				
Revenue	887 097	741 551	190 565	1 819 213
Interest expenses	-	(71 064)	-	(71 064)
Income Tax	-	(105 970)	-	(105 970)
Net profit/(loss) for the period	(179 637)	564 517	190 565	1 642 17
Statement of financial position				
Total Assets	29 882 155	7 519 566	849 095	38 250 816
Total Borrowings	-	(3 424 784)	-	(3 424 784)

Notes

The Company is required to publish financial results for the 9 months ended 30 November 2018 in terms of the Listing Rule 12.19 of the SEM. The abridged unaudited consolidated financial statements for the 3 months ended 30 November 2018 ("Financial Statements") have been prepared in accordance with the measurement and recognition requirements of International Financial Reporting Standards ("IFRS"), the requirements of IAS 34: Interim Financial Reporting and the SEM Listing Rules and the JSE Listing Requirements.

The accounting policies adopted in the preparation of the Financial Statements are in terms of IFRS and are consistent with those applied in the preparation of the audited financial statements of the year ended 28 February 2018.

Copies of the abridged unaudited consolidated financial statements for the 9 months ended 30 November 2018 and the statement of direct and indirect interests of each officer of the Company, pursuant to Rule 8(2)(m) of the Securities (Disclosure Obligations of Reporting Issuers) Rules 2007, are available free of charge, upon request at the registered office of the Company at 5th Floor, Alcthia Building, Cnr Sufferin & Eugene Laurent Streets, Port Louis 21001, Mauritius.

This communiqué is issued pursuant to SEM Listing Rules 11.3 and 12.20 and section 88 of the Securities Act of Mauritius 2005. The Board accepts full responsibility for the accuracy of the information contained in these Financial Statements. The Directors are not aware of any matters or circumstances arising subsequent to the period ended 30 November 2018 that require any additional disclosure or adjustment to the Financial Statements.

Go Life has its primary listing on the Stock Exchange Mauritius and a secondary listing on the AltX of the JSE

By order of the Board

31 January 2019

Executive Directors: Gerhard Jacobus Naudé Mohamed Yusuf Sookiall Marthinus Johannes Wolmarans	Non-Executive Directors: Jean Daniel Laurent Paulin Marie
JSE Sponsor: Arbor Capital Sponsors (Pty) Ltd	Company Secretary: FinAegis Ltd